SHR-A1904

· Shanghai Hengrui Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

7 regulatory and trial events tracked for SHR-A1904, covering 2024-12-12 to 2026-04-09. Get the full timeline:

Most recent: Clinical Trial Update: A Phase II Clinical Study of SHR-A1904 Monotherapy in Second-Line or Later Treatment of Advanced Neuroendocrine Carcinoma [Phase 2]

See pricing